Braun Stacey Associates Inc Incyte Corp Transaction History

Braun Stacey Associates Inc

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 08, 2023	BUY	$70.23 - $86.01 $10.1 Million - $12.3 Million	143,140 New	143,140 $10.3 Million
Q2 2018 Aug 01, 2018	SELL	$60.85 - $83.98 $8.79 Million - $12.1 Million	-144,508 Closed	0 $0
Q1 2018 May 01, 2018	BUY	$83.06 - $100.98 $545,704 - $663,438	6,570 Added 4.76%	144,508 $12 Million
Q4 2017 Jan 30, 2018	SELL	$93.56 - $116.6 $240,168 - $299,312	-2,567 Reduced 1.83%	137,938 $13.1 Million
Q3 2017 Oct 25, 2017	BUY	$109.15 - $138.27 $15.3 Million - $19.4 Million	140,505	140,505 $16.4 Million

643

186M

714K

557K

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $16B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

Get notified when there are updates to the investment portfolio of Braun Stacey Associates Inc, based on Form 13F filings with the SEC.

Stay updated on Braun Stacey Associates Inc with notifications on news.